Corcept Therapeutics
CORT
352 hedge funds and large institutions have $3.2B invested in Corcept Therapeutics in 2026 Q1 according to their latest regulatory filings, with 70 funds opening new positions, 113 increasing their positions, 128 reducing their positions, and 101 closing their positions.
20% more capital invested
Capital invested by funds: $2.67B → $3.2B (+$535M)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
2.01% more ownership
Funds ownership: 72.79% → 74.8% (+2%)
10% less funds holding
Funds holding: 389 → 352 (-37)
12% less repeat investments, than reductions
Existing positions increased: 113 | Existing positions reduced: 128
31% less first-time investments, than exits
New positions opened: 70 | Existing positions closed: 101
50% less call options, than puts
Call options by funds: $49.6M | Put options by funds: $99.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$55.3M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$50.2M |
| 3 |
D.E. Shaw & Co
New York
|
+$37.8M |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$36.9M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$35.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$34.6M |
| 2 |
EIP
Epoch Investment Partners
New York
|
-$28.4M |
| 3 |
JP Morgan Chase
New York
|
-$23.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$22.8M |
| 5 |
Morgan Stanley
New York
|
-$21.4M |
CORT Hedge Fund Activity: Q1 2026 in Review
352 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q1 2026, worth a combined $3.2B — up 20% from $2.67B a quarter earlier.
Sellers outnumbered buyers: 101 funds closed out of CORT and 70 opened new positions — a net loss of 31 holders — while 128 trimmed existing stakes and 113 added.
The largest buyer was First Trust Advisors, adding an estimated $55.3M. The largest seller was TD Asset Management, exiting entirely with an estimated $34.6M sold.
- 352 institutional investors held Corcept Therapeutics (CORT) as of Q1 2026, down from 389 in Q4 2025.
- Funds reported $3.2B of Corcept Therapeutics stock for Q1 2026, up 20% quarter-over-quarter.
- 70 funds opened new Corcept Therapeutics positions in Q1 2026 and 101 closed out, a net change of -31 holders.
- The largest Corcept Therapeutics buyer in Q1 2026 was First Trust Advisors, an estimated $55.3M added.
- The largest Corcept Therapeutics seller in Q1 2026 was TD Asset Management, an estimated $34.6M sold.
Based on aggregated 13F filings for Q1 2026.